SCHEMBL6923288

SCHEMBL6923288

Cc1cc(C(=O)CN(C)CC(C)C)c(C)n1-c1ccc(F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.56
KDM4E B2RXH2 3/20 0.56
USP14 P54578 2/20 0.56
USP7 Q93009 1/20 0.56
SMN1; SMN2 Q16637 10/20 0.55
RAB9A P51151 8/20 0.55
NPC1 O15118 7/20 0.55
HPGD P15428 4/20 0.55
USP5 P45974 1/20 0.55
LMNA P02545 7/20 0.48
HTT P42858 5/20 0.48
TSHR P16473 2/20 0.48
TP53 P04637 1/20 0.48
ALOX15 P16050 1/20 0.48
ALDH1A1 P00352 5/20 0.47
MITF O75030 3/20 0.44
MAPT P10636 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HKDC1 Q2TB90 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19501630 0.90 NOTUM (0.55) NOTUMKDM4EUSP14USP7SMN1; SMN2
SCHEMBL6923175 0.86 SMN1; SMN2 (0.64) NOTUMKDM4EUSP14USP7SMN1; SMN2
SCHEMBL19501868 0.86 NOTUM (0.50) NOTUMKDM4EUSP14USP7SMN1; SMN2
SCHEMBL6922827 0.85 NOTUM (0.59) NOTUMKDM4EUSP14USP7SMN1; SMN2
SCHEMBL6921657 0.85 NOTUM (0.65) NOTUMKDM4EUSP14USP7SMN1; SMN2
SCHEMBL6923099 0.80 SMN1; SMN2 (0.65) NOTUMKDM4EUSP14USP7SMN1; SMN2
SCHEMBL6923043 0.79 SMN1; SMN2 (0.37) NOTUMKDM4EUSP14USP7SMN1; SMN2
SCHEMBL6921653 0.79 NOTUM (0.60) NOTUMKDM4EUSP14USP7SMN1; SMN2
SCHEMBL6922461 0.77 RAB9A (0.63) NOTUMKDM4EUSP14USP7SMN1; SMN2
SCHEMBL18452326 0.77 ALDH1A1 (0.71) NOTUMKDM4EUSP14USP7SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351568-B2 Compositions and methods for enhancing proteasome activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-07-16 US disclosed
US-9849135-B2 USP14 inhibitors for treating or preventing viral infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-12-26 US disclosed
US-9849135-B2 USP14 inhibitors for treating or preventing viral infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-12-26 US disclosed
EP-2528911-B1 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY HARVARD COLLEGE (US) 2017-10-25 EP disclosed
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity THE ASSAY DEPOT, INC. 2016-07-28 US disclosed
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity THE ASSAY DEPOT, INC. 2016-07-28 US disclosed
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2015-11-26 US disclosed
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2015-11-26 US disclosed
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-18 US disclosed
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-18 US disclosed
WO-2014116228-A1 USP14 INHIBITORS FOR TREATING OR PREVENTING VIRAL INFECTIONS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-07-31 WO disclosed
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-21 US disclosed
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-21 US disclosed
WO-2011094545-A2 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections USP14, USP1, USP13 NOTUM 2093/4885KDM4E 1417/4885USP14 1/4885
US-10351568-B2 Compositions and methods for enhancing proteasome activity PSMG3, PSME3, PSMB11 NOTUM 2331/4885KDM4E 2300/4885USP14 12/4885
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSMB11, PSME3 NOTUM 2305/4885KDM4E 2238/4885USP14 6/4885
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSME3, PSMB11 NOTUM 2331/4885KDM4E 2300/4885USP14 12/4885
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation HSPA2, HSPBP1, HSPH1 NOTUM 3253/4885KDM4E 943/4885USP14 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.